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INVITED COMMENT 
Regarding: "The Intermittent Claudication 
Questionnaire: A patient-assessed condition-
specific health outcome measure" 
Martha D. McDaniel, MD, Hanover, NH 
The work reported by Dr Chong and his colleagues in 
this issue ofthe Journal of Vas cuI a r Surgery represents an 
important step fonvard for our patients with intermittent 
claudication. Whereas in the recent past we have mea-
sured success in their care largely with physician-cen-
tered metrics, we will now, with confidence in the valid-
ity of the measures, be able to refine our assessment of 
their overall well being as it pertains to their arterial 
disease. 
Intermittent claudication is not a life-threatening dis-
ease in and of itself. For patients who are relatively asymp-
tomatic from their burden of atherosclerosis in other arte-
rial beds and from other comorbid conditions, however, 
intermittent claudication does threaten the quality of life. 
Without serial assessment of the perception of quality oflife 
of a patient with claudication, physicians purporting to 
treat or follow the progress of the disease will have an 
incomplete picture of its course and effect on the patient. It 
is for this reason that the Trans-Atlantic Consensus Con-
ference on Clinical Trials in Peripheral Artery Disease} 
recommended that disease-specific functional health mea-
surement should be an integral part of primary outcome 
measurement in intermittent claudication. 
Functional health and health-related quality oflife as-
sessment have been topics of general interest tor many 
years. One might argue that there was no need for addi-
tional time, effort, and journal pages to be devoted to the 
development and reporting of an additional instrument for 
assessing these dimensions 111 patients with intermittent 
claudication. There are several reasons why this is not the 
case. First, existing instruments are frequently insensitive 
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to clinically important functional changes occurring in 
patients with claudication. This may be because of 
coarseness in the scale of measurement or because the 
clinically important changes occur "above the ceiling" or 
"below the floor" of the range of function assessed by the 
instrument in question. Second, existing instruments 
may not measure dimensions of function that are impor-
tant to patients with claudication, including the ability to 
pertorm tasks necessary for the maintenance of indepen-
dent living or worry about the future. A third and 
nontrivial issue is that existing measures of generic func-
tional health tend either to be scored as a summary score 
with no actionable detail (eg, EuroQol) or as unidimen-
sional subscores with no overall summary measure (eg, 
Short Form-36). This third problem with existing tunc-
tional health assessment instruments leaves vascular phy-
sicians and surgeons in a suboptimal position. With the 
former type, they do not know what aspect of patient 
functional health has changed, so they cannot act to 
improve their care; with the latter type, they have no 
clear picture of whether functional health is, overall, 
improving or deteriorating. 
It is an important feature of this work that the 
questionnaire has not only been developed but has been 
validated. This may seem arcane but is in fact of para-
mount importance; without rigorous validation, users of 
the instrument cannot know what importance they 
should attach to the responses. Without rigorous valida-
tion, responses to questionnaires should never be used as 
primary measures of health or functional status. 
Complete validation of a health-related survey instru-
ment covers many dimensiom, including the dimensions 
listed in the Table.2 The work under discussion meets all 
these criteria. 
How, then, should practicing vascular physicians and 
surgeons use this instrument? They can begin by mea-
suring the functional health of all patients with clau'dica-
tion they treat and comparing the survey results with 
what they would have expected from their interaction 
apart from the survey. Contrasts can be surprising and 
illuminating. A more conventional use of the survey 
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Dimensions in which health-related survey instruments should be validated 
Dimension Question answered 




Do scores remain stable in the absence of clinically significant change? 
Do patients mind responding? Can they respond in the context of usual clinical 
practice? 
Responsiveness to change Do relevant scores improve as expected given clinical improvement and worsen given 
clinical deterioration? 
Inclusiveness Does instrument measure all aspects of health and/or function that are of general 
importance to population being surveyed? 
results would be to track functional health of individual 
patients over time, especially in the context of a specific 
intervention. By pooling data from similar patients un-
dergoing similar interventions, we can collectively gain a 
better understanding of the efficacy of our clinical care. 
Similarly, practitioners can benchmark their results 
against the results of others and become acquainted with 
ways they can improve their care. 
It is a potential weakness of this work that the survey 
may not be validly applicable to patients with limb-
threatening ischemia and to patients with intermittent 
claudication. This issue aside, though, the first broad-
based foray into functional health assessment in patients 
with arterial disease will represent a worthwhile step 
forward. The instrument that Dr Chong and his col-
leagues have developed and validated can be a tool for all 
of us. 
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